Veru

VERU · NASDAQ

$2.38+$0.07 (+3.03%)TodayMarket closed · Oct 20, 7:58 PM ET

Prev close $2.31

VERU analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $24.99 (+950.0% upside)

Low: $24.24
Now: $2.38
High: $26.25

Upgrades and downgrades

The latest rating actions, newest first

VERU analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
WestPark Capital	Oct 6, 2026	Initiates	Buy	$28.00	47%
Canaccord Genuity	Jun 4, 2026	Maintains	Buy	$25.00	44%
Oppenheimer	May 15, 2026	Maintains	Outperform	$25.00 → $24.00	45%
Canaccord Genuity	Dec 18, 2025	Initiates	Buy	$25.00	44%

The case for and against

Updated Feb 2, 2026

Bull case

Veru Inc. is well-positioned in the growing biopharmaceutical market, particularly due to its late-stage drug candidates enobosarm and sabizabulin, which target unmet needs in cardiometabolic and inflammatory diseases. The substantial increase in market capitalization of competitors in the GLP-1RA space, with growth rates between 135%-250%, underscores the significant market opportunity for Veru’s obesity treatment initiatives, especially as the global spending on obesity medications has surged from ~$3B in 2020 to over $30B by 2024. Additionally, the promising results from recent GLP-1 clinical trials suggest a favorable environment for the expansion of similar therapies, potentially leading to accelerated growth and revenue opportunities for Veru as it seeks to address the demand for muscle preservation treatments.

Bear case

Veru Inc's stock faces a negative outlook primarily due to the inherent risks associated with its late-stage drug development programs for enobosarm and sabizabulin, which may not achieve regulatory success and could hinder future revenue growth. Additionally, the company operates in a competitive environment, leading to potential for lower than expected revenues and increased efficacy and safety expectations from the FDA. Further complicating matters, executive turnover in critical regulatory roles could adversely affect the company's ability to effectively navigate the approval process, creating additional uncertainties for shareholders.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.